In the GL261 mouse model of glioma, combining Treg depletion with CTLA-4 neutralization boosts glioma-specific Tc and Tconv effector T cell responses, while also increasing anti-glioma IgG2A antibody titers; ultimately resulting in complete tumor rejection (Grauer et al., 2007). Here, CTLA4 is linked to central nervous system cancer.